Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + T785-ISAC
- Development stage
- Preclinical
- Lead developer
- Bolt Biotherapeutics
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Intraperitoneal
01
Overview
Rituximab + T785-ISAC is an immune-stimulating antibody conjugate (ISAC) consisting of the anti-CD20 monoclonal antibody rituximab covalently linked to T785, a small-molecule dual agonist of Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8). Developed by Bolt Biotherapeutics, this therapeutic candidate is designed to treat B-cell malignancies by combining targeted antibody therapy with localized innate immune activation. The rituximab component targets CD20-expressing tumor cells, while the Fc domain of the antibody facilitates uptake by myeloid-resident Fcγ receptors. Upon internalization, the T785 payload activates TLR7/8 within the endosomes of myeloid cells (such as macrophages and dendritic cells), promoting their maturation, the release of pro-inflammatory cytokines, and the cross-presentation of tumor antigens. This process converts "cold" tumors into "hot" tumors and elicits a durable, T-cell-mediated systemic antitumor immune response.
- Other names
- rituximab-ISACanti-CD20 ISACanti-CD-20 ISACanti-CD 20 ISAC
02
Targets
CD20 (B-lymphocyte antigen CD20)TLR7/8 (Toll-like receptor 7 and Toll-like receptor 8)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)
Beyond the preview
Go deeper on rituximab + T785-ISAC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + T785-ISAC.